1 patent currently held
87 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2042. from the record
Of the 87 now held by other companies, 84 name Beone Medicines I GmbH as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2042
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Aug 2037 · High confidence
Cited by 36 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
now held by Beone Medicines I GmbH
Also notable
Ends Sep 2033 · High confidence
The most cited patent in this portfolio, cited by 269 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2033.
now held by Beone Medicines I GmbH
Also notable
Ends Apr 2033 · Low confidence
Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
now held by Beone Medicines I GmbH
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 5 of the patents on this record were granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Co-Administration of Mirdametinib and Lifirafenib for Use in Treating Cancers | 1 in force | to Jul 2042 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,667,560 | Co-Administration of Mirdametinib and Lifirafenib for Use in Treating Cancers In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 87 patents in force now held by others · 7 patents ended · 90 applications pending · 38 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
11 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.